325 related articles for article (PubMed ID: 27053454)
1. Global cardiovascular protection in chronic kidney disease.
Ruiz-Hurtado G; Sarafidis P; Fernández-Alfonso MS; Waeber B; Ruilope LM
Nat Rev Cardiol; 2016 Oct; 13(10):603-8. PubMed ID: 27053454
[TBL] [Abstract][Full Text] [Related]
2. How should we modify recommended renin-angiotensin-aldosterone system inhibition when facing the cardiorenal syndrome?
Sexton DJ
Circ Heart Fail; 2014 May; 7(3):536. PubMed ID: 24847129
[No Abstract] [Full Text] [Related]
3. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
Ruiz-Hurtado G; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
[TBL] [Abstract][Full Text] [Related]
4. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology.
Rosano GMC; Tamargo J; Kjeldsen KP; Lainscak M; Agewall S; Anker SD; Ceconi C; Coats AJS; Drexel H; Filippatos G; Kaski JC; Lund L; Niessner A; Ponikowski P; Savarese G; Schmidt TA; Seferovic P; Wassmann S; Walther T; Lewis BS
Eur Heart J Cardiovasc Pharmacother; 2018 Jul; 4(3):180-188. PubMed ID: 29726985
[TBL] [Abstract][Full Text] [Related]
5. Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.
Borghi C; ; Rossi F;
High Blood Press Cardiovasc Prev; 2015 Dec; 22(4):429-44. PubMed ID: 26403596
[TBL] [Abstract][Full Text] [Related]
6. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive suppression of the renin-angiotensin-aldosterone system in chronic kidney disease: covering all of the bases.
Weinberger MH; Luft FC
Kidney Int; 2006 Dec; 70(12):2051-3. PubMed ID: 17136130
[TBL] [Abstract][Full Text] [Related]
8. RAAS inhibition and cardiorenal syndrome.
Onuigbo MA
Curr Hypertens Rev; 2014; 10(2):107-11. PubMed ID: 25549841
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular pathophysiology in chronic kidney disease: opportunities to transition from disease to health.
Tomey MI; Winston JA
Ann Glob Health; 2014; 80(1):69-76. PubMed ID: 24751567
[TBL] [Abstract][Full Text] [Related]
10. Early results of human atrial natriuretic peptide infusion in non-dialysis patients with chronic kidney disease undergoing isolated coronary artery bypass grafting: the NU-HIT trial for CKD-II.
Sezai A; Nakata K; Iida M; Yoshitake I; Wakui S; Hata H; Shiono M
Ann Thorac Cardiovasc Surg; 2014; 20(3):217-22. PubMed ID: 23574999
[TBL] [Abstract][Full Text] [Related]
11. Continuation of Chronic Heart Failure Therapies During Heart Failure Hospitalization - a Review.
Singhania G; Ejaz AA; McCullough PA; Kluger AY; Balamuthusamy S; Dass B; Singhania N; Agarwal A
Rev Cardiovasc Med; 2019 Sep; 20(3):111-120. PubMed ID: 31601085
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection.
Whaley-Connell A; Pavey BS; Chaudhary K; Saab G; Sowers JR
Ther Adv Cardiovasc Dis; 2007 Oct; 1(1):27-35. PubMed ID: 19124393
[TBL] [Abstract][Full Text] [Related]
13. The Impact of Renin-Angiotensin System Blockade on Renal Outcomes and Mortality in Pre-Dialysis Patients with Advanced Chronic Kidney Disease.
Oh YJ; Kim SM; Shin BC; Kim HL; Chung JH; Kim AJ; Ro H; Chang JH; Lee HH; Chung W; Lee C; Jung JY
PLoS One; 2017; 12(1):e0170874. PubMed ID: 28122064
[TBL] [Abstract][Full Text] [Related]
14. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
15. Future drug discovery in renin-angiotensin-aldosterone system intervention.
Tamargo M; Tamargo J
Expert Opin Drug Discov; 2017 Aug; 12(8):827-848. PubMed ID: 28541811
[TBL] [Abstract][Full Text] [Related]
16. Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
Lin CC; Wu YT; Yang WC; Tsai MJ; Liu JS; Yang CY; Li SY; Ou SM; Tarng DC; Hsu CC
PLoS One; 2017; 12(12):e0189126. PubMed ID: 29216260
[TBL] [Abstract][Full Text] [Related]
17. Current drug development challenges in chronic kidney disease (CKD)--identification of individualized determinants of renal progression and premature cardiovascular disease (CVD).
Formentini I; Bobadilla M; Haefliger C; Hartmann G; Loghman-Adham M; Mizrahi J; Pomposiello S; Prunotto M; Meier M
Nephrol Dial Transplant; 2012 Oct; 27 Suppl 3():iii81-8. PubMed ID: 22734108
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone blockade in chronic kidney disease.
Hirsch JS; Drexler Y; Bomback AS
Semin Nephrol; 2014 May; 34(3):307-22. PubMed ID: 25016401
[TBL] [Abstract][Full Text] [Related]
19. Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis.
Barrera-Chimal J; Girerd S; Jaisser F
Kidney Int; 2019 Aug; 96(2):302-319. PubMed ID: 31133455
[TBL] [Abstract][Full Text] [Related]
20. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
